The clinical trial is the first to demonstrate that a monoclonal antibody can prevent malaria in people.

Thursday, August 12, 2021 Monoclonal Antibody Prevents Malaria in Small NIAID Trial Colorized electron micrograph showing malaria parasite (right, blue) attaching to a human red blood cell. The inset shows a detail of the attachment point at higher magnification. Credit: NIAID         One dose of a new monoclonal antibody discovered and developed at NIAID safely prevented malaria for up to nine months in people who were exposed to the malaria parasite. The small, carefully monitored clinical trial is the first to demonstrate that a monoclonal antibody can prevent malaria in people. The trial was sponsored and conducted by scientists from the NIAID Vaccine Research Center and was funded by NIAID. The findings were published yesterday in the New England Journal of Medicine.          To build on this research, a larger NIAID Phase 2 clinical trial is underway in Mali to evaluate the safety and efficacy of the antibody at preventing malaria infection in adults during a six-month malaria season. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107